BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 26049371)

  • 1. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
    Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
    Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
    Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.
    Piccardo A; Lopci E; Conte M; Garaventa A; Foppiani L; Altrinetti V; Nanni C; Bianchi P; Cistaro A; Sorrentino S; Cabria M; Pession A; Puntoni M; Villavecchia G; Fanti S
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):57-71. PubMed ID: 21932116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.
    Melzer HI; Coppenrath E; Schmid I; Albert MH; von Schweinitz D; Tudball C; Bartenstein P; Pfluger T
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1648-58. PubMed ID: 21617976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy.
    Choi YJ; Hwang HS; Kim HJ; Jeong YH; Cho A; Lee JH; Yun M; Lee JD; Kang WJ
    Ann Nucl Med; 2014 May; 28(4):304-13. PubMed ID: 24481823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
    Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
    J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
    Ozkan E; Soydal C; Araz M; Aras G; Ibis E
    Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
    Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
    J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
    Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 131I-MIBG in the diagnosis of primary and metastatic neuroblastoma.
    El-Maghraby T
    Gulf J Oncolog; 2007 Jul; (2):33-41. PubMed ID: 20084722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
    Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
    J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
    Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
    Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.